Bristol-Myers Squibb Compnay

Bristol Meyers Squibb Company

Kevin W Gillman

Paul Michael Scola

David R Langley

John E Starrett, Jr

Jason T Goodrich

Claudio Mapelli

Nicholas A Meanwell

Richard Eric Olson

Michael A Poss

Kenneth M Boy

Yunhui Zhang

Graham S Poindexter

Michael Frederick Parker

Andrew P Degnan

Lawrence B Snyder

Li-Qiang Sun

Eric Mull

Fukang Yang

Hong Huang

Danielle M Bocchino

Qian Zhao

Kap-Sun Yeung

Dharmpal S Dodd

Joanne J Bronson

Omar D Lopez

Eric P Gillis

Bang-Chi Chen

Katharine A Grant-Young

George O Tora

Michael Matthew Miller

Ramkumar Rajamani

Ying Han

Lawrence R Marcin

Michael S Bowsher

Lyndon A M Cornelius

Martin Patrick Allen

Mendi A Higgins

Jonathan L Ditta

Juliang Zhu

Derek John Denhart

William D Schmitz

Huiping Zhang

Maude A Poirier

David Paul Provencal

Daniel J Tenney

Nishith Sanghvi

Leah M Giupponi

Ildiko Antal

Robert H Stoffel

Piyasena Hewawasa

Mark V Silva

Nicolas A Meanwell

Lyndon Am Cornelius

M Nicholas Meanwell

Jason Goodrich

Jr John E Starrett

John E Starrett; Jr

The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

Immunomodulators

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.

Oxazolidinones as modulators of MGLUR5

The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

Immunomodulators acting as antagonists of PD-1

Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system. 

Oxazolidinones as modulators of mGluR5

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both. 

NK-1 and serotonin transporter inhibitors

The present invention provides a novel alpha-(N-sulfonamido)acetamide compound, its pharmaceutical composition, processes thereof and a method for the treatment of Alzheimer's disease and other conditions associated with &#x3b2;-amyloid peptide.

Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production

The present invention provides a method for the treatment of head trauma, traumatic brain injury, and/or dementia pugilistica comprising administering a therapeutically effective amount of (2R)-2-[[(4-chlorophenyl)sulfonyl][[2-fluoro-4-(1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]-5,5,5-trifluoropentanamide.

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.

Substituted heterocyclic ethers and their use in CNS disorders

The present disclosure provides novel deuterated alpha-(N-sulfonamido)acetamide compounds, their pharmaceutical composition, processes thereof and a method for the treatment of Alzheimer's disease, head trauma, traumatic brain injury, and/or dementia pugilistica and/or other conditions associated with &#x3b2;-amyloid peptide.

Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production

Growing community of inventors

Madison, CT, United States of America

Kevin W Gillman